David Norris M.D. will become the PI with the current training Co-director, William Weston M.D. assuming a senior advisor role. Dr. Norris will continue to develop the collaborative interactions critical to this institutional training grant in the future. In the past three training periods 24 of 26 graduates entered full time academic careers and 18 are currently retained in full time academic dermatology. There is one still in training. The training faculty will be enlarged to 9 M.D. & 3 Ph.D. training faculty to include more senior scientists including the Chairman of Cell and Structural Biology, the Director of the Denver Autoinimunity Center and the Head of Human Medical Genetics and the current Editor of the Journal of Allergy and Clinical Immunology. Previous trainee supervisors in the Department of Immunology, the Department of Pharmacology & Divisions of Rheumatology, Medical Oncology and Infectious Diseases of the Department of Medicine are included. The training faculty each have independent funding ($15.4 million for 2001-02, and have each demonstrated successful mentoring of past trainees leading to academic careers. Research areas of interest include: cutaneous molecular virology, melanocyte biology, molecular genetics, melanoma, nonmelanoma skin cancer, oncogenes, cytotoxic mechanisms and programmed cell death, leukotrienes, cytokines including IL1, T cell receptors, photoimmunology, cell signaling and cell surface receptors. Facilities and equipment available to trainees have been upgraded. By 2003, trainees will move to the new University of Colorado Cancer research building with over 7,000 of wet laboratory space available for the dermatology portion of the program with immediate adjacency within the Cancer Center. It is proposed that both Ph.D. and M.D. candidates be included with two trainees recruited each year. All trainees should have demonstrated they are capable of a career in academic dermatology or cutaneous biology. Four essentials of training are proposed: Formal course work, seminars, individual research projects and training in communications skills. Special emphasis on formal coursework in Immunology, Molecular Biology, Molecular Genetics, Cellular Biology, Scientific Ethics, Biostatistics and Management of Hazardous waste is proposed. Trainees will select a project of their own interest or from among a broad list presented to them by the training supervisors. Communication skills of the trainees will be emphasized with specific training in scientific writing and presentations supervised by Drs. Lee & Weston.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Baker, Carl
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830
Shellman, Yiqun G; Lambert, Karoline A; Brauweiler, Anne et al. (2015) SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype. J Invest Dermatol 135:3192-3194
Mukherjee, Nabanita; Reuland, Steven N; Lu, Yan et al. (2015) Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol 135:842-850
Reuland, Steven N; Smith, Shilo M; Bemis, Lynne T et al. (2013) MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol 133:1286-93
Reuland, Steven N; Goldstein, Nathaniel B; Partyka, Katie A et al. (2012) ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open 1:92-100
Reuland, Steven N; Goldstein, Nathaniel B; Partyka, Katie A et al. (2011) The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 6:e24294
Ellis, Lixia Z; Liu, Weimin; Luo, Yuchun et al. (2011) Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1? secretion. Biochem Biophys Res Commun 414:551-6
Anwar, Adil; Norris, David A; Fujita, Mayumi (2011) Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys 508:198-203
Okamoto, Miyako; Liu, Weimin; Luo, Yuchun et al. (2010) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285:6477-88

Showing the most recent 10 out of 55 publications